Shares of Sesen Bio Inc (NASDAQ:SESN) shot up 2.1% on Wednesday . The stock traded as high as $0.58 and last traded at $0.59, 22,374 shares were traded during mid-day trading. A decline of 98% from the average session volume of 1,359,874 shares. The stock had previously closed at $0.58.
Several brokerages recently weighed in on SESN. Zacks Investment Research raised shares of Sesen Bio from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised shares of Sesen Bio from a “sell” rating to a “hold” rating in a research note on Thursday, January 16th.
The company has a market cap of $65.68 million, a PE ratio of -0.51 and a beta of 0.99. The firm has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $1.01.
Institutional investors and hedge funds have recently bought and sold shares of the business. Private Advisor Group LLC grew its holdings in Sesen Bio by 78.9% in the 4th quarter. Private Advisor Group LLC now owns 34,000 shares of the company’s stock valued at $35,000 after buying an additional 15,000 shares during the period. Oxford Asset Management LLP purchased a new stake in Sesen Bio in the 4th quarter valued at about $176,000. Virtu Financial LLC grew its holdings in Sesen Bio by 71.3% in the 4th quarter. Virtu Financial LLC now owns 195,976 shares of the company’s stock valued at $204,000 after buying an additional 81,603 shares during the period. Credit Suisse AG purchased a new stake in Sesen Bio in the 4th quarter valued at about $261,000. Finally, Geode Capital Management LLC grew its holdings in shares of Sesen Bio by 5.4% during the 4th quarter. Geode Capital Management LLC now owns 723,126 shares of the company’s stock worth $752,000 after purchasing an additional 37,081 shares during the period. Institutional investors own 17.24% of the company’s stock.
Sesen Bio Company Profile (NASDAQ:SESN)
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.